The EHR vendor tried to do too much in the past, new CEO David Feinberg told investors. “Going forward, we’re going to change that approach and only focus on a small number of important, high-value areas.”
Despite majority control of Congress, it appears unlikely the Biden administration will be able to pass meaningful pricing reform, though a slimmed-down bill may still be in the works.
The work stoppage at Mercy Hospital in New York caused the facility to scale back operations, and it’s seeing about 100 patients per day versus a usual census of more than 300 patients per day, according to the hospital.
The agency’s priorities include a much-anticipated final guidance on clinical decision support software, more than five years in the making, meant to clarify when CDS meets the definition of a medical device.
It’s unlikely the vendor will step into fully capitated contracts right away, but its CEO said there are degrees of risk Teladoc will take on: moving from clinical measures of care, to risk corridors and ultimately into capitation.
Labor costs are a sticking point this earnings season. But unlike its peers, CHS’ expenses actually dropped slightly during the period.
Despite pandemic pressure, the insurer largely beat Wall Street expectations, and Jefferies analysts said the company delivered “solid overall results.”
The deal with the Medicines Patent Pool is meant to increase access in lower-income countries to molnupiravir, an experimental drug that could become the first oral treatment for COVID-19.
In an interview, Kelly Bliss teased upcoming clients for a new virtual-first primary care product and parsed out Teladoc’s growth strategies for 2022 and beyond.
Prior authorization requirements were the most frequently cited hurdle, while requirements for Medicare’s Quality Payment Program and COVID-19 workplace mandates tied for second, a survey by the medical practices group found.